Panome Bio
E-learning · Bioinformatics
$12Mtotal raised · 3 rounds on record
$6Mlatest round · Venture round · Nov 2024 · 23 mo ago
1backers · Telegraph Hill Partners
$882kgrants · 1 grant · CORDIS
Overview
Panome Bio delivers advanced multi-omics services including Next-Generation Metabolomics, Discovery Proteomics, Transcriptomics, and Integrated Multi-Omics.
Key facts
These are the key facts about Panome Bio on Alion as of Nov 13, 2026. Panome Bio is headquartered in Saint Louis, United States. It was founded in 2022. It has raised $12M in 2 funding rounds. The latest round is Venture - Series Unknown of $6M, announced in 2024.
- Headquarters
- Saint Louis, United StatesAlion company profile, updated Oct 11, 2026
- Founded
- 2022Alion company profile, updated Oct 11, 2026
- Employees
- 10+Alion company profile, an estimated range
- Total raised
- $12MSum of 2 equity rounds Alion knows
- Latest round
- Venture - Series Unknown · $6M · Nov 14, 2024SEC Form D filing · sec.gov
- Visa sponsorship, United States
- 2 · H-1B filings in 12 monthsUS Department of Labor · latest filing May 4, 2026
Official records
Funding and backers
Total raised
$12M
3 rounds on record
Latest round
$6M
Venture round · Nov 2024 · 23 mo ago
Team
11-50
employees, estimated range
Grants
$882k
1 grant · CORDIS
Backers
1
Telegraph Hill Partners
The money's age
Due for its next round
23 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 27
Partnership TD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics Capabilities · streetinsider.com
Feb 25
Launched Panome Bio Introduces MassID, a Major Advance in Untargeted Metabolomics Data Analysis for Biomarker Discovery and Drug Development · YahooFinance
Sep 2, 2025
Won a grant $882k · CORDIS
Feb 25, 2025
Board appointment Panome Bio Welcomes Jean-Pierre Wery to Its Board of Directors as it Prepares for Growth in 2025 · wtnh.com
Nov 14, 2024
Raised a round Venture round $6M · SEC Form D
Feb 15, 2023
Raised a round Venture round $6M · SEC Form D
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2025 | $882k | — | CORDIS |
| Venture round | Nov 2024 | $6M | — | SEC Form D |
| Venture round | Feb 2023 | $6M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Panome Bio Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Edward WeinsteinExecutive Officer, DirectorSEC Form D
Tom CohenExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Dalton Bioanalytics provides multi-omics services powered by the Omni-MS one-shot mass spectrometry platform. Proteomics, metabolomics…
DeepCyte combines single cell metabolomics with AI models to detect drug toxicity early. Reveal why cells turn toxic before drugs reach…
MSAID revolutionizes proteomics analysis with AI, providing cutting-edge software and data analysis services using powerful machine…
Spatial proteomics from H&E. Lattice predicts spatially resolved protein-marker maps from routine H&E, delivered as virtual mIF channels.
Explore the future of spatial biology with Vizgen’s multiomics platforms. Uncover cellular insights through spatial transcriptomics and…
Velsera is a leading provider of omics analytics solutions, powering precision medicine and enhancing the healthcare and life sciences…
Visa sponsorship
2
H-1B filings in 12 months
$93k
Median offered salary
0
Open roles in United States
Who they sponsor
Other biological scientists
2
In the register as Panome Bio Inc., St. Louis, MO
Other sponsors in the same field
Sandbox 
Versatope Therapeutics 
Rezo Therapeutics
Alert me
US Department of Labor · latest filing May 4, 2026 · Visa details by country
People
Edward Weinstein
Executive Officer, Director
Tom Cohen
Executive Officer
David Smoller
Director
Deval Lashkari
Director
Alexander Herzick
Director
Rob Capone
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Telegraph Hill PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
The Hidden Chemistry of Pregnancy
Pregnancy Is More Than Genetics Pregnancy is often discussed through the lens of hormones, genetics and fetal development. But there is another layer influencing maternal and fetal health that researchers are increasingly paying attention to: environmenta
Read more
Report
Surface Proteomics for ADCs and CAR-T Design
Why Cell Therapy Target Selection Is So Difficult Antibody-drug conjugates (ADCs) and CAR-T therapies have reshaped modern oncology, but their success still depends on one deceptively simple question: are we targeting the right protein? In practice, answe
Read more
Report
Advancing the Frontier of Translational Proteomic Insights
Transcript featuring Gary Patti (Panome Bio) and Dipender Gill (Sequoia Genetics) DIPENDER So Gary, great to get a chance to talk again. I know we've had numerous really stimulating conversations about proteomics, genetics, the intersection of science, an
Read more
Report
TD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics Capabilities
Read more
Report
TD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics Capabilities
Read more
Report
A Metabolic Blueprint for Synergistic Cancer Therapy
In the fight against cancer, single-agent treatments often hit a wall as tumors adapt and develop resistance. This is especially true for aggressive cancers like non-small-cell lung cancer (NSCLC) with KRAS and LKB1 mutations, a hard-to-treat subtype. The
Read more
Report
Surface Proteomics for Smarter Drug Target Discovery
Drug development is expensive, slow, and highly unpredictable. Despite major advances in genomics and precision medicine, nearly 90% of drug candidates still fail (Doi: 10.1016/j.apsb.2022.02.002) during clinical development, often because the selected ta
Read more
Report
Untargeted Metabolomics Reimagined: Meet MassID
What if untargeted metabolomics delivered on its promise? For years, untargeted metabolomics has been one of the most compelling approaches in biology: measure broadly, capture molecular diversity and improve biological interpretation and understanding. I
Read more
Report
Decoding Alzheimer's Disease with Multi-Omics
Alzheimer's as a System-Level Disorder via Multi-Omics Alzheimer's disease is not driven by a single pathway, molecule or mutation. Instead, it reflects a system-level breakdown across metabolism, protein regulation and cellular signaling. Yet most studie
Read more
Report
Untargeted vs. Targeted Exposomics Which Do You Need?
In exposomics, there are two fundamentally different ways to explore the chemical world influencing human health and choosing the right one can make or break your study. Think of it like this: Are you searching for something specific or are you trying to
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Saint Louis
United States
HQ
Contact Us
10-50 est. staff
4340 Duncan Avenue, St. Louis, MO, 63110
How to cite this page
Alion, "Panome Bio: key facts", as of Nov 13, 2026. https://alion.io/company/panomebio
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0